

IFW

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 13, 2004

Signature:

*Kurt T. Buechle*  
(Kurt T. Buechle)

Docket No.: 01017/35434B  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Chris Saris

Application No.: 10/622,407

Confirmation No.: 2359

Filed: July 17, 2003

Art Unit: 1646

For: ISOLATION, IDENTIFICATION AND  
CHARACTERIZATION OF TMST2, A  
NOVEL MEMBER OF THE TNF-  
RECEPTOR SUPERGENE FAMILY

Examiner: Eileen O'Hara

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is believed to have been filed before the mailing date of a first Office Action on the merits pursuant to 37 C.F.R. §1.97(b)(3).

Copies of the foreign patent and other documents listed on the attached Form PTO-1449 are supplied unless they were previously cited by, or submitted to, the Office in prosecuting U.S. Patent Application Number 09/612,033, filed July 7, 2000, and relied upon in this application for an earlier filing date under 35 U.S.C. § 120.


In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 13-2855, under Order No. 01017/35434B. A copy of this paper is enclosed.

Dated: July 13, 2004

Respectfully submitted,

By 

Kurt T. Buechle

Registration No.: 54,011

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant

Form PTO-1449 (Modified)

Atty. Docket No.  
01017/35434BSerial No.  
10/622,407Applicant(s)  
Chris SarisFiling Date  
July 17, 2003Art Unit  
1645**INFORMATION DISCLOSURE STATEMENT****U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Issue or Publication Date	Name
	5,605,690	02-25-1997	Jacobs
	5,885,800	03-01-1999	Emery et al.
	5,312,733	05-01-1994	MacLeod
	6,274,339	08-01-2001	Moore et al.
	6,271,366	08-01-2001	Kimura et al.
	2003/0096355	05-22-2003	Zhang
	6,599,716	07-29-2003	Hsu
	2003/0082736	05-01-2003	Smith

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Publication Date	Country
	93/19777	10-14-1993	World Intellectual Property Organization (WIPO)
	94/06476	03-31-1994	World Intellectual Property Organization (WIPO)
	0 648 783	04-19-1995	European Patent Office
	98/35986	07-01-1998	World Intellectual Property Organization (WIPO)
	98/43998	10-01-1998	World Intellectual Property Organization (WIPO)
	99/03992	01-28-1999	World Intellectual Property Organization (WIPO)

**OTHER DOCUMENTS**

	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family", The Rockefeller University Press, Volume 186.
	Pan et al., "TRUDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling," FEBS Letters 424, January 12, 1998, pp. 41-45.

EXAMINER:

DATE CONSIDERED:

Form PTO-1449 (Modified)  <b>INFORMATION DISCLOSURE STATEMENT</b>	Atty. Docket No. 01017/35434B	Serial No. 10/622,407
	Applicant(s) Chris Saris	
	Filing Date July 17, 2003	Art Unit 1645

	Delgli-Esposti, "To die or not to die-the quest of the TRAIL receptors", Journal of Leukocyte Biology, Volume 65, May 1999, pp. 535-542.
	Schneider et al., "Characterization of two receptors for TRAIL", FEBS Letters 416, September 24, 1997, pp. 329-334.
	McFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL", The Journal of Biological Chemistry, Vol. 272, No. 41, July
	Meurs et al., "Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase", Proc. Natl. Acad. Sci. USA, Vol. 90, January 1993, pp. 232-
	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL", The EMBO Journal, Vol. 16, No. 17, 1997, pp. 5386-5397.
	"KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene", Nature Genetics, Vol. 17, October 1997, pp. 141-143.
	Degli-Esposti, et al., "The Novel Receptor TRAIL-R4 Induces NF-kb and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain", Immunity, Vol.
	Naismith et al., "Modularity in the TNF-receptor family", TIBS 23, February 1998, pp. 74-79.
	Hofmann, "The modular nature of apoptotic signaling proteins", CMLS, Vol. 55, 1999, pp.1113-1128.
	Marsters, et al., "A novel receptor for ApoL/TRAIL contains a truncated death domain", Current Biology, Vol. 7, No. 12, 1997, pp. 1003-1006.
	Pitti, et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer", Nature, Vol. 396, December 17, 1998, pp. 699-703.
	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors", Science, Vol 277, August 8, 1997, pp. 818-821.
	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density", Cell, Vol. 89, April 18, 1997, pp. 309-319.
	Griffith et al., "TRAIL: a molecule with multiple receptors and control mechanisms", pp. 559-563.
	Emery et al., "Osteoprotegerin is a Receptor for the Cytotoxic Ligand TRAIL", The Journal of Biological Chemistry, Vol. 273, No. 23, June 5, 1998, pp. 1463-1467.
	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL", Science, Vol. 276, April 4, 1997, pp. 111-113.
	Pan et al., "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL", Science, Vol. 277, August 8, 1997, pp. 815-818.
	Bucay et al., "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification", Genes & Development, Vol. 12, 1998, pp. 1260-1268.
	Wu et al., "Molecular Cloning and Functional Analysis of the Mouse Homologue of the KILLER/DR5 Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death
	Griffith, et al., "Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor-related Cytokine, TRAIL", Vol. 189, No. 8, April 19, 1999, pp. 1343-1353.
	Griffith, et al., "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies", The Journal of Immunology, 1999, pp. 2597-2605.

EXAMINER:	DATE CONSIDERED:
-----------	------------------